SULFADIAZINE SODIUM


Trade Names	SULFADIAZINE SODIUM
Synonyms	NSC-117870 Sodium sulfadiazine Sulfadiazine sodium
Status
Molecule Category	Salt-form
UNII	84CS1P306F
EPA CompTox	DTXSID20203152
Parent Compound:	SULFADIAZINE


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JLDCNMJPBBKAHH-UHFFFAOYSA-N
Smiles	Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Na+]
InChI	InChI=1S/C10H9N4O2S.Na/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H9N4NaO2S
Molecular Weight	272.26
AlogP	0.86
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	97.97
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	17.0

Bioactivity

Mechanism of Action	Action	Reference
Bacterial dihydropteroate synthase inhibitor	INHIBITOR	PubMed PubMed

Cross References

Resources	Reference
ChEMBL	CHEMBL1200351
FDA SRS	84CS1P306F
PubChem	15899898

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).